RESUMEN
Respiratory outcomes in Mucopolysaccharidosis Type I (MPS I), have mainly focused on upper airway obstruction, with the evolution of the restrictive lung disease being poorly documented. We report the long-term pulmonary function outcomes and examine the potential factors affecting these in 2 cohorts of MPS I patients, those who have undergone Haematopoietic Stem Cell Transplantation (HSCT) and those treated with Enzyme Replacement Therapy (ERT). The results were stratified using the American Thoracic Society (ATS) guidelines. 66 patients, capable of adequately performing testing, were identified by a retrospective case note review, 46 transplanted (45 Hurler, 1 Non-Hurler) and 20 having ERT (17 Non-Hurler and 3 Hurler diagnosed too late for HSCT). 5 patients died; 4 in the ERT group including the 3 Hurler patients. Overall 14% of patients required respiratory support (non-invasive ventilation (NIV) or supplemental oxygen)) at the end of follow up. Median length of follow-up was 12.2 (range = 4.9-32) years post HSCT and 14.34 (range = 3.89-20.4) years on ERT. All patients had restrictive lung disease. Cobb angle and male sex were significantly associated with more severe outcomes in the HSCT cohort, with 49% having severe to very severe disease. In the 17 Non-Hurler ERT treated patients there was no variable predictive of severity of disease with 59% having severe to very severe disease. During the course of follow up 67% of the HSCT cohort had no change or improved pulmonary function as did 52% of the ERT patients. However, direct comparison between therapeutic modalities was not possible. This initial evidence would suggest that a degree of restrictive lung disease is present in all treated paediatrically diagnosed MPS I and is still a significant cause of morbidity, though further stratification incorporating diffusing capacity for carbon monoxide (DLCO) is needed.
Asunto(s)
Obstrucción de las Vías Aéreas/terapia , Enfermedades Pulmonares Obstructivas/terapia , Mucopolisacaridosis I/terapia , Adolescente , Adulto , Edad de Inicio , Anciano , Anciano de 80 o más Años , Obstrucción de las Vías Aéreas/complicaciones , Obstrucción de las Vías Aéreas/epidemiología , Obstrucción de las Vías Aéreas/patología , Monóxido de Carbono/metabolismo , Niño , Preescolar , Terapia de Reemplazo Enzimático , Femenino , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Lactante , Enfermedades Pulmonares Obstructivas/complicaciones , Enfermedades Pulmonares Obstructivas/epidemiología , Enfermedades Pulmonares Obstructivas/patología , Masculino , Persona de Mediana Edad , Mucopolisacaridosis I/complicaciones , Mucopolisacaridosis I/epidemiología , Mucopolisacaridosis I/patología , Adulto JovenRESUMEN
The outcome of 110 patients with paediatric onset mucopolysaccharidosis II (MPS II) since the commercial introduction of enzyme replacement therapy (ERT) in England in 2007 is reported. Median length of follow up was 10â¯years 3â¯months (rangeâ¯=â¯1â¯y 2â¯m to 18â¯years 6â¯month). 78 patients were treated with ERT, 18 had no ERT or disease modifying treatment 7 had haematopoietic stem cell transplant, 4 experimental intrathecal therapy and 3 were lost to follow up. There is clear evidence of improved survival (median age of death of ERT treated (nâ¯=â¯16)â¯=â¯15.13â¯years (rangeâ¯=â¯9.53 to 20.58â¯y), and untreated (nâ¯=â¯17)â¯=â¯11.43â¯y (0.5 to 19.13â¯y) pâ¯=â¯.0005). Early introduction of ERT improved respiratory outcome at 16â¯years, the median FVC (% predicted) of those in whom ERT initiated <8â¯yearsâ¯=â¯69% (rangeâ¯=â¯34-86%) and 48% (25-108) (pâ¯=â¯.045) in those started >8â¯years. However, ERT appears to have minimal impact on hearing, carpal tunnel syndrome or progression of cardiac valvular disease. Cardiac valvular disease occurred in 18/46 (40%), with progression occurring most frequently in the aortic valve 13/46 (28%). The lack of requirement for neurosurgical intervention in the first 8â¯years of life suggests that targeted imaging based on clinical symptomology would be safe in this age group after baseline assessments. There is also emerging evidence that the neurological phenotype is more nuanced than the previously recognized dichotomy of severe and attenuated phenotypes in patients presenting in early childhood.
Asunto(s)
Terapia de Reemplazo Enzimático , Mucopolisacaridosis II/tratamiento farmacológico , Adolescente , Niño , Preescolar , Recolección de Datos , Progresión de la Enfermedad , Inglaterra , Estudios de Seguimiento , Humanos , Lactante , Mucopolisacaridosis II/mortalidad , Fenotipo , Estudios Retrospectivos , Factores de Tiempo , Resultado del TratamientoRESUMEN
Morquio A (Mucopolysaccharidosis IVA; MPS IVA) is an autosomal recessive lysosomal storage disorder caused by partial or total deficiency of the enzyme galactosamine-6-sulfate sulfatase (GALNS; also known as N-acetylgalactosamine-6-sulfate sulfatase) encoded by the GALNS gene. Patients who inherit two mutated GALNS gene alleles have a decreased ability to degrade the glycosaminoglycans (GAGs) keratan sulfate and chondroitin 6-sulfate, thereby causing GAG accumulation within lysosomes and consequently pleiotropic disease. GALNS mutations occur throughout the gene and many mutations are identified only in single patients or families, causing difficulties both in mutation detection and interpretation. In this study, molecular analysis of 163 patients with Morquio A identified 99 unique mutations in the GALNS gene believed to negatively impact GALNS protein function, of which 39 are previously unpublished, together with 26 single-nucleotide polymorphisms. Recommendations for the molecular testing of patients, clear reporting of sequence findings, and interpretation of sequencing data are provided.
Asunto(s)
Condroitinsulfatasas/genética , Condroitinsulfatasas/metabolismo , Mucopolisacaridosis IV/genética , Mutación , Células Cultivadas , Niño , Preescolar , Femenino , Estudios de Asociación Genética , Pruebas Genéticas , Genotipo , Glicosaminoglicanos/metabolismo , Humanos , Lactante , Lisosomas/metabolismo , Masculino , Mucopolisacaridosis IV/diagnóstico , Polimorfismo de Nucleótido SimpleRESUMEN
In this study, 103 unrelated South-American patients with mucopolysaccharidosis type II (MPS II) were investigated aiming at the identification of iduronate-2-sulfatase (IDS) disease causing mutations and the possibility of some insights on the genotype-phenotype correlation The strategy used for genotyping involved the identification of the previously reported inversion/disruption of the IDS gene by PCR and screening for other mutations by PCR/SSCP. The exons with altered mobility on SSCP were sequenced, as well as all the exons of patients with no SSCP alteration. By using this strategy, we were able to find the pathogenic mutation in all patients. Alterations such as inversion/disruption and partial/total deletions of the IDS gene were found in 20/103 (19%) patients. Small insertions/deletions/indels (<22 bp) and point mutations were identified in 83/103 (88%) patients, including 30 novel mutations; except for a higher frequency of small duplications in relation to small deletions, the frequencies of major and minor alterations found in our sample are in accordance with those described in the literature.
Asunto(s)
Exones , Iduronato Sulfatasa/genética , Mucopolisacaridosis II/genética , Mutación , Adulto , Femenino , Estudios de Asociación Genética , Técnicas de Genotipaje , Humanos , Mucopolisacaridosis II/diagnóstico , Mucopolisacaridosis II/patología , Análisis de Secuencia de ADN , Índice de Severidad de la Enfermedad , América del SurRESUMEN
We describe the case of a boy recently diagnosed with an attenuated form of mucopolysacchararidosis VI (MPS VI, Maroteaux-Lamy syndrome). The Y210C mutation has not been described previously in the homozygous state, although this is a common ARSB mutation. His phenotype is essentially musculoskeletal. Urine screening tests based on measuring total GAG may miss this presentation as total GAGs were not elevated in the patient (although the electrophoresis pattern was clearly abnormal). In this phenotype the benefit of ERT remains to be established.
Asunto(s)
Homocigoto , Mucopolisacaridosis VI/genética , Mutación/genética , N-Acetilgalactosamina-4-Sulfatasa/genética , Adolescente , Humanos , Masculino , Mucopolisacaridosis VI/diagnóstico por imagen , Fenotipo , RadiografíaRESUMEN
Hurler Syndrome is corrected by allogeneic BMT by the action of donor enzyme on recipient tissue. In this paper, we describe monitoring of 39 patients transplanted in two centres to determine donor chimerism, enzyme level and residual substrate - expressed as dermatan sulphate to chondroitin sulphate ratio. We show that in fully engrafted recipients, the enzyme level, expressed as mumol/g total protein/h, post-transplant is 24.2 from an unrelated donor and 10.2 from a heterozygote family donor (P<0.0001). There is a tight relationship between mean post-transplant enzyme level and residual substrate - Spearman's rank correlation coefficient (Rho) was -0.76 and -0.80 at 12 and 24 months, respectively (P<0.0001). We propose that these differences affect patient outcome. As unrelated donor transplant outcomes improve and especially given the higher levels of donor cell engraftment following cord transplants, our data might influence donor selection where only heterozygote-matched family members are available.
Asunto(s)
Quimerismo , Trasplante de Células Madre Hematopoyéticas , Iduronidasa/metabolismo , Mucopolisacaridosis I/terapia , Sulfatos de Condroitina/metabolismo , Sulfatos de Condroitina/orina , Trasplante de Células Madre de Sangre del Cordón Umbilical , Dermatán Sulfato/metabolismo , Dermatán Sulfato/orina , Glicosaminoglicanos/orina , Heterocigoto , Prueba de Histocompatibilidad , Humanos , Trasplante Homólogo/fisiología , Resultado del TratamientoRESUMEN
We describe a cohort of 14 Hurler-Scheie patients homozygous for the p.Leu490Pro missense mutation in the alpha-L-iduronidase gene. Now based in the UK, they are all of Pakistani/Kashmiri descent; 64% were female; 11/14 (79%) had a sibling or cousin with MPS I and the parents are consanguineous in all cases. The median age at diagnosis was 1.8 years (range from antenatal diagnosis to 16.5 years). Twelve were on ERT with recombinant human alpha-L-iduronidase (IDUA; Laronidase, Genzyme) for a median duration of 22.5 months (range 2-71 months) and median age at commencement of ERT was 8.6 years (range 0.4-23.1 years). There was clear improvement in the size of liver and spleen as well as reduction in urine glycosaminoglycans (GAGs). The mean (range) urine GAG levels in mg/mmol creatinine were 63.4 (28.9-105.6), 28.3 (10.9-41.4), 22.8 (12.1-43.1), 15.7 (9.2-24.8) and 16.3 (10.1-21.0) at commencement, 3 months post ERT, 6 months post ERT, 12 months post ERT and 24 months post ERT, respectively. Effects on growth were not clear as there does not seem to be an obvious trend of increase or decrease in height after commencement of ERT and this seems to be the case regardless of the age at which ERT was started.